IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, IDEXX Laboratories, Inc. (IDXX) trades at a EV/FCF of 36.0×. Over the past ten years it has ranged from 32.4× (September 2026) to 114× (February 2023); the current reading is higher than 2% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 57.2× 19.74%
FY2024 47.7× (20.37%)
FY2023 60.0× (33.45%)
FY2022 90.1× 0.16%
FY2021 89.9× 12.56%
FY2020 79.9× 1.34%
FY2019 78.9× 30.26%
FY2018 60.5× 28.37%
FY2017 47.2× 20.22%
FY2016 39.2× (22.36%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 33.8× (20.52%)
Mar 2026 42.5× (25.60%)
Dec 2025 57.2× (4.17%)
Sep 2025 59.6× (4.36%)
42 more quarters

Against its own ten years

Low 32.4× High 114×
Ten-year median 63.0×
Current reading's percentile 2

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on IDXX